维莫非尼和曲美替尼治疗期间黑色素瘤的表皮趋向性进展 - Suppr | 超能文献

Epidermotropic progression of melanoma during therapy with vemurafenib and trametinib.

作者信息

Ferrara Gerardo, Cacitti Veronica, Improta Giuseppina, Lo Re Giovanni, Corradin Maria Teresa

机构信息

Department of Oncology, Anatomic Pathology Unit, Geatano Rummo General Hospital, Benevento, Italy.

Department of Anatomic Pathology, Santa Maria degli Angeli Hospital, Pordenone, Italy.

出版信息

J Am Acad Dermatol. 2016 Oct;75(4):e133-e135. doi: 10.1016/j.jaad.2016.03.006.

DOI:10.1016/j.jaad.2016.03.006

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Epidermotropic progression of melanoma during therapy with vemurafenib and trametinib.维莫非尼和曲美替尼治疗期间黑色素瘤的表皮趋向性进展

J Am Acad Dermatol. 2016 Oct;75(4):e133-e135. doi: 10.1016/j.jaad.2016.03.006.

2

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.达拉非尼联合曲美替尼与维莫非尼单药治疗不可切除或转移性皮肤 BRAF Val600 突变阳性黑色素瘤患者的健康相关生活质量比较（COMBI-v）：一项开放标签、随机、3 期临床试验结果。

Lancet Oncol. 2015 Oct;16(13):1389-98. doi: 10.1016/S1470-2045(15)00087-X.

3

Improved overall survival in melanoma with combined dabrafenib and trametinib.达拉非尼和曲美替尼联合治疗可改善黑色素瘤患者的总生存期。

N Engl J Med. 2015 Jan 1;372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16.

4

Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.一名局部晚期BRAF V600E突变黑色素瘤患者成功接受（新）辅助BRAF靶向治疗。

Melanoma Res. 2015 Apr;25(2):180-3. doi: 10.1097/CMR.0000000000000145.

5

BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.BRAF 抑制用于晚期局部区域 BRAF V600E 突变型黑色素瘤：一种潜在的新辅助治疗策略。

Melanoma Res. 2016 Feb;26(1):83-7. doi: 10.1097/CMR.0000000000000214.

6

Rapid evolution of combination therapy in melanoma.黑色素瘤联合治疗的快速发展

N Engl J Med. 2014 Nov 13;371(20):1929-30. doi: 10.1056/NEJMe1411158.

7

Successful re-challenge with anti-BRAF and anti-MEK in a patient with symptomatic melanoma flare.一名有症状性黑色素瘤发作的患者成功再次接受抗BRAF和抗MEK治疗。

Eur J Cancer. 2017 Sep;82:25-26. doi: 10.1016/j.ejca.2017.05.039. Epub 2017 Jun 21.

8

Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.BRAF 抑制剂单独及联合 MEK 抑制剂治疗转移性黑色素瘤的皮肤毒性作用。

JAMA Dermatol. 2015 Oct;151(10):1103-9. doi: 10.1001/jamadermatol.2015.1745.

9

Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.转移性黑色素瘤靶向治疗期间的毛发和指甲不良事件。

Eur J Dermatol. 2016 Jun 1;26(3):232-9. doi: 10.1684/ejd.2016.2747.

10

Rapid regression of metastatic brain tumours in a melanoma patient after dabrafenib/trametinib therapy.一名黑色素瘤患者在接受达拉非尼/曲美替尼治疗后转移性脑肿瘤迅速消退。

Eur J Dermatol. 2017 Oct 1;27(5):548-549. doi: 10.1684/ejd.2017.3095.

引用本文的文献

1

Dermoscopic assessment of skin toxicities in patients with melanoma during treatment with vemurafenib.维莫非尼治疗期间黑色素瘤患者皮肤毒性的皮肤镜评估

Postepy Dermatol Alergol. 2018 Feb;35(1):39-46. doi: 10.5114/ada.2018.73163. Epub 2018 Feb 20.